Entera Bio Ltd. (NASDAQ: ENTX) completed a private placement led by BVF Partners L.P., issuing 7,827,789 units at $1.2775 per unit. Each unit consists of one ordinary share and a five‑year warrant to purchase 1.5 shares at $1.24 per share, allowing the company to raise roughly $10 million in gross proceeds before expenses and up to $24.5 million if all warrants are exercised for cash.
The financing is earmarked to launch the company’s Phase 3 registrational study of EB613, its first oral anabolic tablet for osteoporosis, and to support general working capital and corporate purposes. By securing this capital, Entera extends its cash runway beyond the previously projected end of Q3 2026, giving the company additional time to execute the trial and pursue other pipeline programs.
Entera’s prior capital raises—including a $6.6 million private placement in December 2023—have been used to fund research and development and to maintain operations. The new private placement reinforces investor confidence in the company’s oral biologics platform and its potential to capture a sizable share of the osteoporosis market, which is currently dominated by injectable therapies.
While the announcement does not include a detailed breakdown of how the $10 million will be allocated within the Phase 3 study, the company’s guidance indicates that the funds will cover clinical trial costs, regulatory filings, and related expenses. The private placement also provides liquidity for unforeseen operational needs, positioning Entera to navigate the high‑cost landscape of late‑stage drug development.
Overall, the private placement represents a critical milestone for Entera Bio, providing the financial foundation to advance its lead asset, strengthen its balance sheet, and maintain flexibility for future growth initiatives.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.